nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Methylprednisolone—ankylosing spondylitis	0.305	0.5	CpDpCtD
Sulindac—osteoarthritis—Prednisone—ankylosing spondylitis	0.305	0.5	CpDpCtD
Sulindac—PTGS2—Sulfasalazine—ankylosing spondylitis	0.0522	0.176	CbGbCtD
Sulindac—PTGS2—Triamcinolone—ankylosing spondylitis	0.0522	0.176	CbGbCtD
Sulindac—PTGS2—Betamethasone—ankylosing spondylitis	0.0448	0.151	CbGbCtD
Sulindac—PTGS1—Sulfasalazine—ankylosing spondylitis	0.0441	0.149	CbGbCtD
Sulindac—ALB—Prednisone—ankylosing spondylitis	0.0263	0.0888	CbGbCtD
Sulindac—PTGS2—Dexamethasone—ankylosing spondylitis	0.026	0.0879	CbGbCtD
Sulindac—CYP1A1—Dexamethasone—ankylosing spondylitis	0.022	0.0742	CbGbCtD
Sulindac—SLC22A6—Methotrexate—ankylosing spondylitis	0.0155	0.0523	CbGbCtD
Sulindac—ALB—Methotrexate—ankylosing spondylitis	0.0132	0.0445	CbGbCtD
Sulindac—PTGDR2—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.0069	0.187	CbGpPWpGaD
Sulindac—PTGDR2—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00458	0.125	CbGpPWpGaD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0024	0.0651	CbGpPWpGaD
Sulindac—MAPK3—Integrins in angiogenesis—EDIL3—ankylosing spondylitis	0.00153	0.0415	CbGpPWpGaD
Sulindac—MAPK3—IL17 signaling pathway—IL17A—ankylosing spondylitis	0.000725	0.0197	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.00064	0.0174	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.000615	0.0167	CbGpPWpGaD
Sulindac—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000566	0.0154	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.000536	0.0146	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000471	0.0128	CbGpPWpGaD
Sulindac—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000459	0.0125	CbGpPWpGaD
Sulindac—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000449	0.0122	CbGpPWpGaD
Sulindac—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000432	0.159	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000425	0.156	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000425	0.156	CbGdCrCtD
Sulindac—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—ankylosing spondylitis	0.000423	0.0115	CbGpPWpGaD
Sulindac—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000415	0.153	CbGdCrCtD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000403	0.011	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000377	0.0102	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000364	0.0099	CbGpPWpGaD
Sulindac—MAPK3—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.000355	0.00965	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.000344	0.00934	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000341	0.00926	CbGpPWpGaD
Sulindac—MAPK3—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00034	0.00923	CbGpPWpGaD
Sulindac—MAPK3—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000326	0.00887	CbGpPWpGaD
Sulindac—MAPK3—IL-6 signaling pathway—CRP—ankylosing spondylitis	0.000319	0.00866	CbGpPWpGaD
Sulindac—MAPK3—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000313	0.00851	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000309	0.0084	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000309	0.0084	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000307	0.00835	CbGpPWpGaD
Sulindac—MAPK3—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.00029	0.00788	CbGpPWpGaD
Sulindac—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000261	0.0957	CbGdCrCtD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.00026	0.00706	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000259	0.00705	CbGpPWpGaD
Sulindac—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000256	0.0942	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000256	0.0942	CbGdCrCtD
Sulindac—MAPK3—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000254	0.00689	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—B3GNT2—ankylosing spondylitis	0.000252	0.00685	CbGpPWpGaD
Sulindac—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000251	0.0921	CbGdCrCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00025	0.0068	CbGpPWpGaD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000247	0.0067	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000237	0.00645	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.000211	0.00574	CbGpPWpGaD
Sulindac—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000208	0.00565	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000206	0.0056	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-C—ankylosing spondylitis	0.000204	0.00555	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000203	0.00551	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.0002	0.00543	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000197	0.00534	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—IL1A—ankylosing spondylitis	0.000187	0.00507	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000183	0.00496	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000174	0.00472	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.00017	0.00462	CbGpPWpGaD
Sulindac—MAPK3—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.000166	0.00452	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000165	0.00449	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000165	0.00448	CbGpPWpGaD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000164	0.00444	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000158	0.00428	CbGpPWpGaD
Sulindac—MAPK3—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000157	0.00426	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000153	0.00416	CbGpPWpGaD
Sulindac—MAPK3—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.000147	0.004	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000141	0.00384	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000136	0.0037	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000136	0.0037	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIR3DL1—ankylosing spondylitis	0.000135	0.00367	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000135	0.00366	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000134	0.00364	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000133	0.00361	CbGpPWpGaD
Sulindac—MAPK3—Ceramide signaling pathway—TNF—ankylosing spondylitis	0.000132	0.00359	CbGpPWpGaD
Sulindac—Syncope—Triamcinolone—ankylosing spondylitis	0.000132	0.00247	CcSEcCtD
Sulindac—Vertigo—Methylprednisolone—ankylosing spondylitis	0.000132	0.00247	CcSEcCtD
Sulindac—Syncope—Methylprednisolone—ankylosing spondylitis	0.000131	0.00246	CcSEcCtD
Sulindac—Oedema—Prednisolone—ankylosing spondylitis	0.00013	0.00244	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00013	0.00244	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—ankylosing spondylitis	0.00013	0.00244	CcSEcCtD
Sulindac—Dysuria—Methotrexate—ankylosing spondylitis	0.00013	0.00244	CcSEcCtD
Sulindac—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000129	0.00242	CcSEcCtD
Sulindac—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000129	0.00241	CcSEcCtD
Sulindac—MAPK3—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000128	0.00348	CbGpPWpGaD
Sulindac—Shock—Prednisolone—ankylosing spondylitis	0.000128	0.0024	CcSEcCtD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	0.000128	0.00348	CbGpPWpGaD
Sulindac—Convulsion—Triamcinolone—ankylosing spondylitis	0.000127	0.00238	CcSEcCtD
Sulindac—Tachycardia—Prednisolone—ankylosing spondylitis	0.000127	0.00238	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.000127	0.00238	CcSEcCtD
Sulindac—Convulsion—Methylprednisolone—ankylosing spondylitis	0.000127	0.00238	CcSEcCtD
Sulindac—Hypertension—Triamcinolone—ankylosing spondylitis	0.000127	0.00238	CcSEcCtD
Sulindac—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000126	0.00237	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000126	0.00236	CcSEcCtD
Sulindac—Myalgia—Triamcinolone—ankylosing spondylitis	0.000125	0.00234	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—ankylosing spondylitis	0.000125	0.00234	CcSEcCtD
Sulindac—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000125	0.00234	CcSEcCtD
Sulindac—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000125	0.00234	CcSEcCtD
Sulindac—Depression—Methotrexate—ankylosing spondylitis	0.000124	0.00232	CcSEcCtD
Sulindac—Flushing—Prednisone—ankylosing spondylitis	0.000124	0.00232	CcSEcCtD
Sulindac—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000124	0.00232	CcSEcCtD
Sulindac—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000124	0.00232	CcSEcCtD
Sulindac—Discomfort—Triamcinolone—ankylosing spondylitis	0.000123	0.00231	CcSEcCtD
Sulindac—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000123	0.00231	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000123	0.0023	CcSEcCtD
Sulindac—Renal failure—Methotrexate—ankylosing spondylitis	0.000122	0.00229	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—CARD9—ankylosing spondylitis	0.000122	0.00331	CbGpPWpGaD
Sulindac—Angioedema—Dexamethasone—ankylosing spondylitis	0.000122	0.00228	CcSEcCtD
Sulindac—Angioedema—Betamethasone—ankylosing spondylitis	0.000122	0.00228	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—ankylosing spondylitis	0.000121	0.00227	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-B—ankylosing spondylitis	0.000121	0.00328	CbGpPWpGaD
Sulindac—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000121	0.00226	CcSEcCtD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	0.00012	0.00327	CbGpPWpGaD
Sulindac—Malaise—Dexamethasone—ankylosing spondylitis	0.00012	0.00225	CcSEcCtD
Sulindac—Malaise—Betamethasone—ankylosing spondylitis	0.00012	0.00225	CcSEcCtD
Sulindac—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00012	0.00225	CcSEcCtD
Sulindac—Oedema—Triamcinolone—ankylosing spondylitis	0.00012	0.00225	CcSEcCtD
Sulindac—Vertigo—Dexamethasone—ankylosing spondylitis	0.00012	0.00224	CcSEcCtD
Sulindac—Vertigo—Betamethasone—ankylosing spondylitis	0.00012	0.00224	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.00012	0.00325	CbGpPWpGaD
Sulindac—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00012	0.00224	CcSEcCtD
Sulindac—Syncope—Dexamethasone—ankylosing spondylitis	0.000119	0.00224	CcSEcCtD
Sulindac—Syncope—Betamethasone—ankylosing spondylitis	0.000119	0.00224	CcSEcCtD
Sulindac—Arrhythmia—Prednisone—ankylosing spondylitis	0.000119	0.00223	CcSEcCtD
Sulindac—Sweating—Methotrexate—ankylosing spondylitis	0.000119	0.00223	CcSEcCtD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000119	0.00322	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000118	0.00322	CbGpPWpGaD
Sulindac—Haematuria—Methotrexate—ankylosing spondylitis	0.000118	0.00222	CcSEcCtD
Sulindac—MAPK3—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000118	0.00321	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL1A—ankylosing spondylitis	0.000118	0.00321	CbGpPWpGaD
Sulindac—Shock—Triamcinolone—ankylosing spondylitis	0.000118	0.00221	CcSEcCtD
Sulindac—Insomnia—Prednisolone—ankylosing spondylitis	0.000118	0.00221	CcSEcCtD
Sulindac—Alopecia—Prednisone—ankylosing spondylitis	0.000118	0.00221	CcSEcCtD
Sulindac—Shock—Methylprednisolone—ankylosing spondylitis	0.000118	0.0022	CcSEcCtD
Sulindac—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—PPARD—Adipogenesis—TNF—ankylosing spondylitis	0.000117	0.00317	CbGpPWpGaD
Sulindac—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000117	0.00219	CcSEcCtD
Sulindac—MAPK3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000116	0.00316	CbGpPWpGaD
Sulindac—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000116	0.00217	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000116	0.00217	CcSEcCtD
Sulindac—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000116	0.00217	CcSEcCtD
Sulindac—Convulsion—Betamethasone—ankylosing spondylitis	0.000115	0.00216	CcSEcCtD
Sulindac—Convulsion—Dexamethasone—ankylosing spondylitis	0.000115	0.00216	CcSEcCtD
Sulindac—Hypertension—Betamethasone—ankylosing spondylitis	0.000115	0.00216	CcSEcCtD
Sulindac—Hypertension—Dexamethasone—ankylosing spondylitis	0.000115	0.00216	CcSEcCtD
Sulindac—Myalgia—Betamethasone—ankylosing spondylitis	0.000113	0.00213	CcSEcCtD
Sulindac—Myalgia—Dexamethasone—ankylosing spondylitis	0.000113	0.00213	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000112	0.00305	CbGpPWpGaD
Sulindac—Discomfort—Dexamethasone—ankylosing spondylitis	0.000112	0.0021	CcSEcCtD
Sulindac—Discomfort—Betamethasone—ankylosing spondylitis	0.000112	0.0021	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000112	0.00304	CbGpPWpGaD
Sulindac—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000112	0.00209	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—ankylosing spondylitis	0.000111	0.00209	CcSEcCtD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000111	0.00302	CbGpPWpGaD
Sulindac—PTGDR2—tendon—ankylosing spondylitis	0.000111	0.215	CbGeAlD
Sulindac—Vision blurred—Prednisone—ankylosing spondylitis	0.000109	0.00205	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000109	0.00205	CcSEcCtD
Sulindac—ALB—Folate Metabolism—CRP—ankylosing spondylitis	0.000109	0.00296	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000109	0.00204	CcSEcCtD
Sulindac—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000109	0.00204	CcSEcCtD
Sulindac—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000109	0.00204	CcSEcCtD
Sulindac—Oedema—Betamethasone—ankylosing spondylitis	0.000109	0.00204	CcSEcCtD
Sulindac—Oedema—Dexamethasone—ankylosing spondylitis	0.000109	0.00204	CcSEcCtD
Sulindac—Insomnia—Triamcinolone—ankylosing spondylitis	0.000108	0.00203	CcSEcCtD
Sulindac—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000108	0.00203	CcSEcCtD
Sulindac—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000108	0.00202	CcSEcCtD
Sulindac—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000108	0.00202	CcSEcCtD
Sulindac—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000107	0.00201	CcSEcCtD
Sulindac—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000107	0.00201	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—ankylosing spondylitis	0.000107	0.00201	CcSEcCtD
Sulindac—Anaemia—Prednisone—ankylosing spondylitis	0.000107	0.00201	CcSEcCtD
Sulindac—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000107	0.00291	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000107	0.00291	CbGpPWpGaD
Sulindac—Shock—Betamethasone—ankylosing spondylitis	0.000107	0.002	CcSEcCtD
Sulindac—Shock—Dexamethasone—ankylosing spondylitis	0.000107	0.002	CcSEcCtD
Sulindac—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000107	0.002	CcSEcCtD
Sulindac—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000106	0.00199	CcSEcCtD
Sulindac—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000106	0.00199	CcSEcCtD
Sulindac—Tachycardia—Betamethasone—ankylosing spondylitis	0.000106	0.00199	CcSEcCtD
Sulindac—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000106	0.00199	CcSEcCtD
Sulindac—Angioedema—Prednisone—ankylosing spondylitis	0.000106	0.00199	CcSEcCtD
Sulindac—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000105	0.00198	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000105	0.00197	CcSEcCtD
Sulindac—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000105	0.00197	CcSEcCtD
Sulindac—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000105	0.00197	CcSEcCtD
Sulindac—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000105	0.00197	CcSEcCtD
Sulindac—Malaise—Prednisone—ankylosing spondylitis	0.000105	0.00196	CcSEcCtD
Sulindac—Vertigo—Prednisone—ankylosing spondylitis	0.000104	0.00195	CcSEcCtD
Sulindac—Syncope—Prednisone—ankylosing spondylitis	0.000104	0.00195	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—ankylosing spondylitis	0.000104	0.00195	CcSEcCtD
Sulindac—Anorexia—Betamethasone—ankylosing spondylitis	0.000104	0.00194	CcSEcCtD
Sulindac—Anorexia—Dexamethasone—ankylosing spondylitis	0.000104	0.00194	CcSEcCtD
Sulindac—Urticaria—Prednisolone—ankylosing spondylitis	0.000103	0.00194	CcSEcCtD
Sulindac—Fatigue—Triamcinolone—ankylosing spondylitis	0.000103	0.00194	CcSEcCtD
Sulindac—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000103	0.00193	CcSEcCtD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000102	0.00278	CbGpPWpGaD
Sulindac—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000102	0.00191	CcSEcCtD
Sulindac—Hypotension—Betamethasone—ankylosing spondylitis	0.000102	0.0019	CcSEcCtD
Sulindac—Hypotension—Dexamethasone—ankylosing spondylitis	0.000102	0.0019	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000101	0.00275	CbGpPWpGaD
Sulindac—Convulsion—Prednisone—ankylosing spondylitis	0.0001	0.00188	CcSEcCtD
Sulindac—Hypertension—Prednisone—ankylosing spondylitis	0.0001	0.00188	CcSEcCtD
Sulindac—Chills—Methotrexate—ankylosing spondylitis	9.99e-05	0.00187	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	9.9e-05	0.00186	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	9.9e-05	0.00186	CcSEcCtD
Sulindac—Arthralgia—Prednisone—ankylosing spondylitis	9.87e-05	0.00185	CcSEcCtD
Sulindac—Myalgia—Prednisone—ankylosing spondylitis	9.87e-05	0.00185	CcSEcCtD
Sulindac—Feeling abnormal—Triamcinolone—ankylosing spondylitis	9.87e-05	0.00185	CcSEcCtD
Sulindac—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	9.85e-05	0.00185	CcSEcCtD
Sulindac—Alopecia—Methotrexate—ankylosing spondylitis	9.84e-05	0.00184	CcSEcCtD
Sulindac—Insomnia—Dexamethasone—ankylosing spondylitis	9.83e-05	0.00184	CcSEcCtD
Sulindac—Insomnia—Betamethasone—ankylosing spondylitis	9.83e-05	0.00184	CcSEcCtD
Sulindac—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	9.77e-05	0.00183	CcSEcCtD
Sulindac—Paraesthesia—Dexamethasone—ankylosing spondylitis	9.76e-05	0.00183	CcSEcCtD
Sulindac—Paraesthesia—Betamethasone—ankylosing spondylitis	9.76e-05	0.00183	CcSEcCtD
Sulindac—Discomfort—Prednisone—ankylosing spondylitis	9.75e-05	0.00183	CcSEcCtD
Sulindac—PTGS2—skeletal joint—ankylosing spondylitis	9.65e-05	0.187	CbGeAlD
Sulindac—Hypersensitivity—Prednisolone—ankylosing spondylitis	9.6e-05	0.0018	CcSEcCtD
Sulindac—Dyspepsia—Dexamethasone—ankylosing spondylitis	9.57e-05	0.00179	CcSEcCtD
Sulindac—Dyspepsia—Betamethasone—ankylosing spondylitis	9.57e-05	0.00179	CcSEcCtD
Sulindac—Urticaria—Triamcinolone—ankylosing spondylitis	9.51e-05	0.00178	CcSEcCtD
Sulindac—Urticaria—Methylprednisolone—ankylosing spondylitis	9.49e-05	0.00178	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—ankylosing spondylitis	9.49e-05	0.00178	CcSEcCtD
Sulindac—Body temperature increased—Triamcinolone—ankylosing spondylitis	9.47e-05	0.00177	CcSEcCtD
Sulindac—Oedema—Prednisone—ankylosing spondylitis	9.46e-05	0.00177	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—ankylosing spondylitis	9.46e-05	0.00177	CcSEcCtD
Sulindac—Decreased appetite—Dexamethasone—ankylosing spondylitis	9.45e-05	0.00177	CcSEcCtD
Sulindac—Decreased appetite—Betamethasone—ankylosing spondylitis	9.45e-05	0.00177	CcSEcCtD
Sulindac—MAPK3—Disease—ANTXR2—ankylosing spondylitis	9.44e-05	0.00257	CbGpPWpGaD
Sulindac—Fatigue—Dexamethasone—ankylosing spondylitis	9.37e-05	0.00176	CcSEcCtD
Sulindac—Fatigue—Betamethasone—ankylosing spondylitis	9.37e-05	0.00176	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—PTGER4—ankylosing spondylitis	9.31e-05	0.00253	CbGpPWpGaD
Sulindac—Shock—Prednisone—ankylosing spondylitis	9.31e-05	0.00175	CcSEcCtD
Sulindac—Tachycardia—Prednisone—ankylosing spondylitis	9.24e-05	0.00173	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—ankylosing spondylitis	9.15e-05	0.00172	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—ankylosing spondylitis	9.13e-05	0.00171	CcSEcCtD
Sulindac—PPARD—Metabolism—B3GNT2—ankylosing spondylitis	9.13e-05	0.00248	CbGpPWpGaD
Sulindac—Anorexia—Prednisone—ankylosing spondylitis	9.02e-05	0.00169	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—ankylosing spondylitis	8.99e-05	0.00169	CcSEcCtD
Sulindac—Anaemia—Methotrexate—ankylosing spondylitis	8.96e-05	0.00168	CcSEcCtD
Sulindac—Feeling abnormal—Betamethasone—ankylosing spondylitis	8.96e-05	0.00168	CcSEcCtD
Sulindac—Feeling abnormal—Dexamethasone—ankylosing spondylitis	8.96e-05	0.00168	CcSEcCtD
Sulindac—MAPK3—Cellular responses to stress—IL1A—ankylosing spondylitis	8.93e-05	0.00243	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	8.89e-05	0.00167	CcSEcCtD
Sulindac—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	8.89e-05	0.00167	CcSEcCtD
Sulindac—MAPK3—Alzheimers Disease—TNF—ankylosing spondylitis	8.87e-05	0.00241	CbGpPWpGaD
Sulindac—Hypersensitivity—Triamcinolone—ankylosing spondylitis	8.82e-05	0.00165	CcSEcCtD
Sulindac—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	8.8e-05	0.00165	CcSEcCtD
Sulindac—Malaise—Methotrexate—ankylosing spondylitis	8.74e-05	0.00164	CcSEcCtD
Sulindac—Vertigo—Methotrexate—ankylosing spondylitis	8.71e-05	0.00163	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—ankylosing spondylitis	8.67e-05	0.00163	CcSEcCtD
Sulindac—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	8.65e-05	0.00235	CbGpPWpGaD
Sulindac—Urticaria—Dexamethasone—ankylosing spondylitis	8.63e-05	0.00162	CcSEcCtD
Sulindac—Urticaria—Betamethasone—ankylosing spondylitis	8.63e-05	0.00162	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	8.62e-05	0.00162	CcSEcCtD
Sulindac—Dizziness—Prednisolone—ankylosing spondylitis	8.61e-05	0.00161	CcSEcCtD
Sulindac—Asthenia—Triamcinolone—ankylosing spondylitis	8.59e-05	0.00161	CcSEcCtD
Sulindac—Body temperature increased—Betamethasone—ankylosing spondylitis	8.59e-05	0.00161	CcSEcCtD
Sulindac—Body temperature increased—Dexamethasone—ankylosing spondylitis	8.59e-05	0.00161	CcSEcCtD
Sulindac—Asthenia—Methylprednisolone—ankylosing spondylitis	8.57e-05	0.00161	CcSEcCtD
Sulindac—Insomnia—Prednisone—ankylosing spondylitis	8.56e-05	0.0016	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	8.52e-05	0.00232	CbGpPWpGaD
Sulindac—Paraesthesia—Prednisone—ankylosing spondylitis	8.5e-05	0.00159	CcSEcCtD
Sulindac—Pruritus—Triamcinolone—ankylosing spondylitis	8.47e-05	0.00159	CcSEcCtD
Sulindac—Pruritus—Methylprednisolone—ankylosing spondylitis	8.45e-05	0.00159	CcSEcCtD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	8.45e-05	0.0023	CbGpPWpGaD
Sulindac—Convulsion—Methotrexate—ankylosing spondylitis	8.4e-05	0.00157	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—ankylosing spondylitis	8.33e-05	0.00156	CcSEcCtD
Sulindac—Chest pain—Methotrexate—ankylosing spondylitis	8.25e-05	0.00155	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—ankylosing spondylitis	8.25e-05	0.00155	CcSEcCtD
Sulindac—Myalgia—Methotrexate—ankylosing spondylitis	8.25e-05	0.00155	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—ankylosing spondylitis	8.23e-05	0.00154	CcSEcCtD
Sulindac—Rash—Prednisolone—ankylosing spondylitis	8.21e-05	0.00154	CcSEcCtD
Sulindac—Dermatitis—Prednisolone—ankylosing spondylitis	8.2e-05	0.00154	CcSEcCtD
Sulindac—Diarrhoea—Methylprednisolone—ankylosing spondylitis	8.18e-05	0.00153	CcSEcCtD
Sulindac—MAPK3—Immune System—IL1R2—ankylosing spondylitis	8.17e-05	0.00222	CbGpPWpGaD
Sulindac—Fatigue—Prednisone—ankylosing spondylitis	8.16e-05	0.00153	CcSEcCtD
Sulindac—Headache—Prednisolone—ankylosing spondylitis	8.16e-05	0.00153	CcSEcCtD
Sulindac—Discomfort—Methotrexate—ankylosing spondylitis	8.15e-05	0.00153	CcSEcCtD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	8.13e-05	0.00221	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	8.11e-05	0.0022	CbGpPWpGaD
Sulindac—Constipation—Prednisone—ankylosing spondylitis	8.09e-05	0.00152	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	8.06e-05	0.00219	CbGpPWpGaD
Sulindac—Dizziness—Triamcinolone—ankylosing spondylitis	7.92e-05	0.00148	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—ankylosing spondylitis	7.91e-05	0.00148	CcSEcCtD
Sulindac—Dizziness—Methylprednisolone—ankylosing spondylitis	7.9e-05	0.00148	CcSEcCtD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	7.85e-05	0.00213	CbGpPWpGaD
Sulindac—Feeling abnormal—Prednisone—ankylosing spondylitis	7.8e-05	0.00146	CcSEcCtD
Sulindac—Asthenia—Dexamethasone—ankylosing spondylitis	7.8e-05	0.00146	CcSEcCtD
Sulindac—Asthenia—Betamethasone—ankylosing spondylitis	7.8e-05	0.00146	CcSEcCtD
Sulindac—MAPK3—Immune System—ERAP1—ankylosing spondylitis	7.75e-05	0.00211	CbGpPWpGaD
Sulindac—Thrombocytopenia—Methotrexate—ankylosing spondylitis	7.74e-05	0.00145	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—ankylosing spondylitis	7.74e-05	0.00145	CcSEcCtD
Sulindac—Nausea—Prednisolone—ankylosing spondylitis	7.74e-05	0.00145	CcSEcCtD
Sulindac—Pruritus—Dexamethasone—ankylosing spondylitis	7.69e-05	0.00144	CcSEcCtD
Sulindac—Pruritus—Betamethasone—ankylosing spondylitis	7.69e-05	0.00144	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—ankylosing spondylitis	7.65e-05	0.00143	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—HLA-C—ankylosing spondylitis	7.64e-05	0.00208	CbGpPWpGaD
Sulindac—Vomiting—Triamcinolone—ankylosing spondylitis	7.62e-05	0.00143	CcSEcCtD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	7.61e-05	0.00207	CbGpPWpGaD
Sulindac—Vomiting—Methylprednisolone—ankylosing spondylitis	7.6e-05	0.00142	CcSEcCtD
Sulindac—Rash—Triamcinolone—ankylosing spondylitis	7.55e-05	0.00142	CcSEcCtD
Sulindac—Dermatitis—Triamcinolone—ankylosing spondylitis	7.54e-05	0.00141	CcSEcCtD
Sulindac—Anorexia—Methotrexate—ankylosing spondylitis	7.54e-05	0.00141	CcSEcCtD
Sulindac—Rash—Methylprednisolone—ankylosing spondylitis	7.53e-05	0.00141	CcSEcCtD
Sulindac—Dermatitis—Methylprednisolone—ankylosing spondylitis	7.53e-05	0.00141	CcSEcCtD
Sulindac—Urticaria—Prednisone—ankylosing spondylitis	7.52e-05	0.00141	CcSEcCtD
Sulindac—Headache—Triamcinolone—ankylosing spondylitis	7.5e-05	0.00141	CcSEcCtD
Sulindac—Headache—Methylprednisolone—ankylosing spondylitis	7.49e-05	0.0014	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—ankylosing spondylitis	7.48e-05	0.0014	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	7.47e-05	0.00203	CbGpPWpGaD
Sulindac—Diarrhoea—Betamethasone—ankylosing spondylitis	7.44e-05	0.00139	CcSEcCtD
Sulindac—Diarrhoea—Dexamethasone—ankylosing spondylitis	7.44e-05	0.00139	CcSEcCtD
Sulindac—Hypotension—Methotrexate—ankylosing spondylitis	7.39e-05	0.00139	CcSEcCtD
Sulindac—PTGS2—synovial membrane of synovial joint—ankylosing spondylitis	7.33e-05	0.142	CbGeAlD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	7.23e-05	0.00197	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	7.22e-05	0.00196	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	7.22e-05	0.00196	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	7.21e-05	0.00135	CcSEcCtD
Sulindac—Dizziness—Dexamethasone—ankylosing spondylitis	7.19e-05	0.00135	CcSEcCtD
Sulindac—Dizziness—Betamethasone—ankylosing spondylitis	7.19e-05	0.00135	CcSEcCtD
Sulindac—Insomnia—Methotrexate—ankylosing spondylitis	7.15e-05	0.00134	CcSEcCtD
Sulindac—Nausea—Triamcinolone—ankylosing spondylitis	7.11e-05	0.00133	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—ankylosing spondylitis	7.1e-05	0.00133	CcSEcCtD
Sulindac—Nausea—Methylprednisolone—ankylosing spondylitis	7.1e-05	0.00133	CcSEcCtD
Sulindac—MAPK3—Immune System—CARD9—ankylosing spondylitis	7.09e-05	0.00193	CbGpPWpGaD
Sulindac—Dyspnoea—Methotrexate—ankylosing spondylitis	7.05e-05	0.00132	CcSEcCtD
Sulindac—Somnolence—Methotrexate—ankylosing spondylitis	7.03e-05	0.00132	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—ankylosing spondylitis	6.97e-05	0.00131	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—ankylosing spondylitis	6.96e-05	0.00131	CcSEcCtD
Sulindac—Vomiting—Dexamethasone—ankylosing spondylitis	6.91e-05	0.0013	CcSEcCtD
Sulindac—Vomiting—Betamethasone—ankylosing spondylitis	6.91e-05	0.0013	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—ankylosing spondylitis	6.88e-05	0.00129	CcSEcCtD
Sulindac—Rash—Dexamethasone—ankylosing spondylitis	6.85e-05	0.00128	CcSEcCtD
Sulindac—Rash—Betamethasone—ankylosing spondylitis	6.85e-05	0.00128	CcSEcCtD
Sulindac—Dermatitis—Dexamethasone—ankylosing spondylitis	6.85e-05	0.00128	CcSEcCtD
Sulindac—Dermatitis—Betamethasone—ankylosing spondylitis	6.85e-05	0.00128	CcSEcCtD
Sulindac—Fatigue—Methotrexate—ankylosing spondylitis	6.82e-05	0.00128	CcSEcCtD
Sulindac—Headache—Dexamethasone—ankylosing spondylitis	6.81e-05	0.00128	CcSEcCtD
Sulindac—Headache—Betamethasone—ankylosing spondylitis	6.81e-05	0.00128	CcSEcCtD
Sulindac—Asthenia—Prednisone—ankylosing spondylitis	6.79e-05	0.00127	CcSEcCtD
Sulindac—Pruritus—Prednisone—ankylosing spondylitis	6.7e-05	0.00126	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—MMP3—ankylosing spondylitis	6.63e-05	0.0018	CbGpPWpGaD
Sulindac—Feeling abnormal—Methotrexate—ankylosing spondylitis	6.52e-05	0.00122	CcSEcCtD
Sulindac—PTGS2—cartilage tissue—ankylosing spondylitis	6.49e-05	0.126	CbGeAlD
Sulindac—Diarrhoea—Prednisone—ankylosing spondylitis	6.48e-05	0.00121	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	6.47e-05	0.00121	CcSEcCtD
Sulindac—Nausea—Betamethasone—ankylosing spondylitis	6.46e-05	0.00121	CcSEcCtD
Sulindac—Nausea—Dexamethasone—ankylosing spondylitis	6.46e-05	0.00121	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—TNF—ankylosing spondylitis	6.44e-05	0.00175	CbGpPWpGaD
Sulindac—Urticaria—Methotrexate—ankylosing spondylitis	6.28e-05	0.00118	CcSEcCtD
Sulindac—Dizziness—Prednisone—ankylosing spondylitis	6.26e-05	0.00117	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—ankylosing spondylitis	6.25e-05	0.00117	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	6.1e-05	0.00166	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	6.06e-05	0.00165	CbGpPWpGaD
Sulindac—Vomiting—Prednisone—ankylosing spondylitis	6.02e-05	0.00113	CcSEcCtD
Sulindac—Rash—Prednisone—ankylosing spondylitis	5.97e-05	0.00112	CcSEcCtD
Sulindac—Dermatitis—Prednisone—ankylosing spondylitis	5.96e-05	0.00112	CcSEcCtD
Sulindac—Headache—Prednisone—ankylosing spondylitis	5.93e-05	0.00111	CcSEcCtD
Sulindac—AKR1B1—tendon—ankylosing spondylitis	5.89e-05	0.114	CbGeAlD
Sulindac—Hypersensitivity—Methotrexate—ankylosing spondylitis	5.83e-05	0.00109	CcSEcCtD
Sulindac—Asthenia—Methotrexate—ankylosing spondylitis	5.67e-05	0.00106	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	5.65e-05	0.00153	CbGpPWpGaD
Sulindac—Nausea—Prednisone—ankylosing spondylitis	5.62e-05	0.00105	CcSEcCtD
Sulindac—PTGS2—Disease—ANTXR2—ankylosing spondylitis	5.61e-05	0.00153	CbGpPWpGaD
Sulindac—Pruritus—Methotrexate—ankylosing spondylitis	5.6e-05	0.00105	CcSEcCtD
Sulindac—MAPK3—Disease—B3GNT2—ankylosing spondylitis	5.56e-05	0.00151	CbGpPWpGaD
Sulindac—Diarrhoea—Methotrexate—ankylosing spondylitis	5.41e-05	0.00101	CcSEcCtD
Sulindac—Dizziness—Methotrexate—ankylosing spondylitis	5.23e-05	0.000981	CcSEcCtD
Sulindac—Vomiting—Methotrexate—ankylosing spondylitis	5.03e-05	0.000943	CcSEcCtD
Sulindac—Rash—Methotrexate—ankylosing spondylitis	4.99e-05	0.000935	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—ankylosing spondylitis	4.98e-05	0.000934	CcSEcCtD
Sulindac—Headache—Methotrexate—ankylosing spondylitis	4.95e-05	0.000929	CcSEcCtD
Sulindac—ALB—Folate Metabolism—TNF—ankylosing spondylitis	4.93e-05	0.00134	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—ankylosing spondylitis	4.85e-05	0.00132	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	4.84e-05	0.00132	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—ankylosing spondylitis	4.7e-05	0.000881	CcSEcCtD
Sulindac—PPARD—tendon—ankylosing spondylitis	4.63e-05	0.0898	CbGeAlD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	4.6e-05	0.00125	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	4.6e-05	0.00125	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.52e-05	0.00123	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-B—ankylosing spondylitis	4.52e-05	0.00123	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-C—ankylosing spondylitis	4.45e-05	0.00121	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	4.38e-05	0.00119	CbGpPWpGaD
Sulindac—MAPK3—tendon—ankylosing spondylitis	4.27e-05	0.0828	CbGeAlD
Sulindac—MAPK3—Innate Immune System—CRP—ankylosing spondylitis	3.99e-05	0.00109	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	3.92e-05	0.00106	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1RN—ankylosing spondylitis	3.87e-05	0.00105	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—TLR4—ankylosing spondylitis	3.83e-05	0.00104	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	3.83e-05	0.00104	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	3.49e-05	0.000949	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD79A—ankylosing spondylitis	3.39e-05	0.000922	CbGpPWpGaD
Sulindac—PTGS2—Disease—B3GNT2—ankylosing spondylitis	3.31e-05	0.000899	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—MMP3—ankylosing spondylitis	3.22e-05	0.000875	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1A—ankylosing spondylitis	2.78e-05	0.000756	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	2.77e-05	0.000753	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—ankylosing spondylitis	2.77e-05	0.000752	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTGER4—ankylosing spondylitis	2.67e-05	0.000726	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—ankylosing spondylitis	2.63e-05	0.000715	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.6e-05	0.000708	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	2.46e-05	0.000668	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-A—ankylosing spondylitis	2.44e-05	0.000663	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CRP—ankylosing spondylitis	2.33e-05	0.000632	CbGpPWpGaD
Sulindac—MAPK3—Disease—HLA-A—ankylosing spondylitis	2.25e-05	0.000612	CbGpPWpGaD
Sulindac—ALB—Metabolism—B3GNT2—ankylosing spondylitis	2.24e-05	0.000609	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TLR4—ankylosing spondylitis	2.23e-05	0.000606	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—ankylosing spondylitis	2.05e-05	0.000556	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP3—ankylosing spondylitis	1.9e-05	0.000517	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.57e-05	0.000426	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—ankylosing spondylitis	1.34e-05	0.000364	CbGpPWpGaD
Sulindac—PTGS1—tendon—ankylosing spondylitis	1.16e-05	0.0225	CbGeAlD
Sulindac—PTGS2—tendon—ankylosing spondylitis	1.11e-05	0.0215	CbGeAlD
